These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36045377)

  • 21. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reporting reimbursement price decisions for onco-hematology drugs in Spain.
    Elvira D; Torres F; Vives R; Puig G; Obach M; Gay D; Varón D; de Pando T; Tabernero J; Pontes C
    Front Public Health; 2023; 11():1265323. PubMed ID: 37942255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient advocacy group involvement in health technology assessments: an observational study.
    Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
    Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System: the cefiderocol example.
    Calleja MÁ; Badia X
    Int J Technol Assess Health Care; 2022 May; 38(1):e48. PubMed ID: 35591781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Price differentiation and transparency in the global pharmaceutical marketplace.
    Ridley DB
    Pharmacoeconomics; 2005; 23(7):651-8. PubMed ID: 15987224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.
    Lopert R; Ruiz F; Chalkidou K
    Health Policy; 2013 Oct; 112(3):202-8. PubMed ID: 23953877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do tariffs and prices correspond with costs? A case study of orthotic braces.
    Simoens S; Debruyne H; Moldenaers I; Guillaume P; De Coster S; Van den Steen D; Van de Sande S; Ramaekers D; Lona M
    J Med Econ; 2008; 11(2):245-54. PubMed ID: 19450083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
    Drummond M; Jönsson B; Rutten F; Stargardt T
    Eur J Health Econ; 2011 Jun; 12(3):263-71. PubMed ID: 20803050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need.
    Dionne PA; Ali F; Grobler M
    J Health Econ Outcomes Res; 2015; 3(1):13-23. PubMed ID: 34430665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient advocate perspectives on involvement in HTA: an international snapshot.
    Scott AM; Wale JL;
    Res Involv Engagem; 2017; 3():2. PubMed ID: 29062527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism.
    Zin CS; Taufek NH; Bux SH
    Front Public Health; 2020; 8():551328. PubMed ID: 33365294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.